Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01551498 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)
A Phase 2 study, sponsored by Rock Creek Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT01551498 is a Phase 2 study that has completed, run by Rock Creek Pharmaceuticals. The registered enrollment target is 165 participants.
The verdict
NCT01551498, a Phase 2 study, has completed, sponsored by Rock Creek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety, tolerability, and potential effects of Anatabloc dietary supplementation on antithyroid autoantibodies, thyroid structure, and thyroid function in subjects with autoimmune thyroiditis.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Anatabloc Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01551498
The ClinicalTrials.gov registry entry for NCT01551498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rock Creek Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01551498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01551498 about?
NCT01551498 is a clinical study titled "Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)". This is a study to evaluate the safety, tolerability, and potential effects of Anatabloc dietary supplementation on antithyroid autoantibodies, thyroid structure, and thyroid function in subjects with autoimmune thyroiditis.
What is the current status of trial NCT01551498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2012-03. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01551498?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Anatabloc Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01551498?
This trial is sponsored by Rock Creek Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.